Cell Resources Corporation

§01

Basic information

BASIC

Head office: 1-12-1 Uchi-Kanda, Chiyoda-ku, Tokyo
Chief executive: Kotaro Arita
Capital: 80,000,000
Employees (non-consolidated)
Employees (consolidated)
Start date: 2022-04-21
End date

§02

Websites

1 DOMAINS

https://cellresources.co.jp/

§03

Business

3

Supply of cell raw materialsManufacture of specific cell processed productsManufacture of regenerative medicine products

§04

Related companies

6 COMPANIES

Company name	Group	Parent	Subsidiary	Customer	Supplier	Alliance	Bank	Shareholder
Regencell Bioscience Holdings Limited Alliance
Yokogawa Electric Corporation Alliance
Alfresa Holdings Corporation
Alfresa Holdings Corporation
Tohoku Alfresa Corporation
Haneda Mirai Development Corporation

Names without a link are companies not yet registered in OpenBizGraph

§05

Network

NETWORK

§06

History

1 EVENTS

2022-04-21

Cell Resources Corporation was established.

§07

News

20 ARTICLES

2026-10-07

Notice of Joint Exhibition at BioJapan 2026

Cell Resources Co., Ltd. will jointly exhibit at BioJapan 2026, held from October 7 to 9, 2026, at Pacifico Yokohama, together with four subsidiaries and alliance partner Sowaneer Co., Ltd. We will introduce the features of the platform 'PATH-Solution', which supports entry into the Japanese market, and will address inquiries about market entry by leveraging each company's expertise. Cell Resources Co., Ltd. will handle the development and manufacturing functions of regenerative medicine and related products.

2026-10-07

Notice of Joint Exhibition at BioJapan 2026

Cell Resources Inc. will participate in BioJapan 2026, introducing and providing consultation on the Japan Market Entry Support Platform "PATH-Solution".

2026-10-01

Website update notice

We updated the "Business Introduction" section on the website and expanded the content of the "CDMO business".

2026-10-01

Cell Resources Updates Its Website

Cell Resources updated its website, with expanded information about its contract development and manufacturing organization (CDMO) business.

2026-08-03

Cell Resources Commences Operations at Haneda PDC

Cell Resources has commenced operations at the Haneda Process Development Center (Haneda PDC), a development and manufacturing hub for regenerative medicine within Haneda Innovation City. At this site, we support academia and venture companies in drug discovery seeds by developing and establishing manufacturing methods from early stages, addressing pharmaceutical regulatory compliance, and exploring logistics methods, thereby strengthening our CDMO service provision.

2026-08-03

Cell Resources strengthens CDMO capabilities as Haneda PDC begins operations

Cell Resources Co., Ltd. today began operations at the Haneda Process Development Center (Haneda PDC) in Haneda Innovation City. The new site is equipped to establish manufacturing processes and address regulatory requirements in order to provide CDMO services supporting regenerative medicine projects from drug discovery through commercialization.

2026-08-03

Cell Resources begins operations at Haneda PDC to strengthen CDMO capabilities

Cell Resources Inc. began operations at its Haneda Process Development Center (Haneda PDC) in Haneda Innovation City. The PDC supports the development and manufacturing of drug discovery seeds in regenerative medicine and is intended to strengthen the company's CDMO capabilities. By providing early support for establishing manufacturing processes and addressing regulatory requirements for regenerative medicine products, the center aims to accelerate practical application and commercialization by academic institutions and startups.

2026-07-14

Website Update Notice

We updated our website. In the business introduction, we expanded the domestic raw material (Master Cell) supply business and added pharmaceutical consulting to our service lineup. We also changed the Value about us.

2026-07-14

Start of Providing Umbilical Cord and Amniotic Membrane Derived MSCs

Cell Resources Inc. has begun providing human umbilical cord and amniotic membrane-derived mesenchymal stromal cells (MSCs) for research purposes. These cells are offered as a new option for use in regenerative medicine product development and in research and development of reagents, automated culture systems, and other regenerative medicine-related studies.

2026-07-14

Notice of website update

We have updated our website. In the business overview, we expanded our offering of domestically sourced raw materials (master cells) and added pharmaceutical and regulatory consulting to our service lineup. We also revised the values described in the About Us section.